This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Novel Therapeutic Approaches of EGFR-, ALK-Rearranged Targeted Therapies and Immunotherapy of Lung Cancer

Novel Therapeutic Approaches of EGFR-, ALK-Rearranged Targeted Therapies and Immunotherapy of Lung Cancer

Format

Webcast

Time to Complete

2.25 hours

Released

October 6, 2017

Expires

October 6, 2018
Add to Queue


Maximum Credits

2.25 / AMA PRA Category 1 Credit(s)TM
2.25 / CE for Nurses

Accredited Provider

Jointly provided by CancerNet, LLC, A. Webb Roberts Center for CME of Baylor Scott & White Health, and Amedco

Commercial Supporter

Supported by Boehringer Ingelheim Pharmaceuticals, Inc

Program Description

This webcast is intended to improve care of patients with lung cancer by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is designed to meet the educational needs of hematologists/oncologists and other healthcare professionals who diagnose, treat, and manage patients with lung cancer.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Outline the clinical data supporting the optimal use of epidermal growth factor receptor (EGFR) and EGFR-T790M–inhibitors in the treatment of non-small cell lung cancer (NSCLC)
  • Identify strategies to overcome secondary or acquired resistance to EGFR-positive and EGFR-T790M–positive NSCLC
  • Identify strategies in the treatment of NSCLC patients with ALK inhibitors and strategies to overcome secondary or acquired ALK TKI resistance in patients with NSCLC
  • Explain the mechanisms of action of checkpoint inhibitors and their impact on novel combination therapies in NSCLC

Conflict Of Interest Disclosure Policy

It is the policy of the A. Webb Roberts Center for CME of Baylor Scott & White Health and Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Faculty

David Gerber, MD
Associate Professor
Division of Hematology-Oncology
Co-Leader, Experimental Therapeutics Program
Co-Director, Lung Disease Oriented Team
Harold C. Simmons Cancer Center
University of Texas Southwestern Medical Center
Dallas, TX

Dr. Gerber discloses that he is on advisory boards (compensated) of Guardant Health; advisory boards (not compensated) of Boehringer-Ingelheim, BMS, Celgene, Genentech, Peregrine, and Synta; and has received research funding from ArQule, Astra-Zeneca, Boehringer-Ingelheim, BerGenBio, ImClone, ImmunoGen, and Peregrine.

Don L. Gibbons, MD, PhD
Assistant Professor
Depts. of Thoracic, Head/Neck Medical Oncology & Molecular and Cellular Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Gibbons discloses that he is on the advisory boards of Janssen R&D and AstraZeneca; and received research funding from Janssen R&D and AstraZeneca.

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE webcast:

David Gerber, MD, discloses that he is on advisory boards (compensated) of Guardant Health, advisory boards (not compensated) of Boehringer-Ingelheim, BMS, Celgene, Genentech, Peregrine, Synta, and has received
research funding from ArQule, Astra-Zeneca, Boehringer-Ingelheim, BerGenBio, ImClone, ImmunoGen, Peregrine.

Don L. Gibbons, MD, PhD, discloses that he is on the advisory board of Janssen R&D and AstraZeneca, received research funding from Janssen R&D and AstraZeneca

Kamatham A. Naidu, PhD (CancerNet), has no relevant financial relationships to disclose.

Credit

2.25

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the co-providership of A. Webb Roberts Center for CME of Baylor Scott & White Health and CancerNet. The A. Webb Roberts Center for CME of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

A. Webb Roberts Center for CME of Baylor Scott & White Health designates this enduring material for a maximum of 2.25 AMA PRA Category 1 CreditsTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

2.25

Type

CE for Nurses

Accreditation Statement

Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and CancerNet, LLC.

Designation Statement

This course provides a maximum of 2.25 contact hours.

Disclosure of Unlabeled Use

It is the policy of the A. Webb Roberts Center for CME of Baylor Scott & White Health and Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Non-Endorsement of Products

The Amedco do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Instructions

There are no fees for participating and receiving CE credit for this webcast. During the period October 6, 2017 through October 6, 2018, participants must read all the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CE Provider at certificate@amedcoemail.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Amedco observes privacy and confidentiality of CE information and personal information of CE participants. Third parties receive only aggregated data about CE activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue